findmyKOL

Angela Dispenzieri, MD

Enriched profile

Professor of Medicine and of Laboratory Medicine and Pathology; Consultant, Division of Hematology, Department of Internal Medicine (Serene M. and Frances C. Durling Professor of Medicine) · Mayo Clinic

ORCIDNPI
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyHematologyFocusMultiple Myeloma Research and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2001–2022

Angela Dispenzieri is Professor of Medicine and of Laboratory Medicine and Pathology; Consultant, Division of Hematology, Department of Internal Medicine (Serene M. and Frances C. Durling Professor of Medicine) at Mayo Clinic. OpenAlex indexes 2,490 publications with 100,475 citations (h-index 146); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology profiles in the findmyKOL directory. Clarivate lists Angela Dispenzieri as a Highly Cited Researcher (Clinical Medicine, 2021; Cross-Field, 2019, 2022-2023).

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Angela Dispenzieri, M.D., is Professor of Medicine and of Laboratory Medicine and Pathology at Mayo Clinic, Rochester, Minnesota. The public record shows 2,490 publications with 100,475 citations (h-index 146), centered on Multiple Myeloma Research and Treatments, Amyloidosis: Diagnosis, Treatment, Outcomes, Protein Degradation and Inhibitors. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 9 companies, 5 NIH-funded awards (2001–2022).

  • Most recent indexed publication: 2026 · Journal of clinical oncology
  • Top research focus: Multiple Myeloma Research and Treatments
  • 13 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 9 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Multiple Myeloma8 trialsAmyloidosis4 trialsST Elevation Myocardial Infarction2 trialsImmunoglobulin Light-chain Amyloidosis2 trialsPain1 trialPlasmacytoma1 trialPOEMS Syndrome1 trialLeukemia (AML/ALL/CML/CLL)

Research focus

OpenAlex concept fingerprint
Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, OutcomesProtein Degradation and InhibitorsChronic Lymphocytic Leukemia ResearchCancer Treatment and Pharmacology

Drugs & molecules

across trials, industry payments and publications
Revlimidgeneric · LenalidomideClinical trials2Industry payments3Publications9Stem CellClinical trials1Industry paymentsPublications22Darzalexgeneric · DaratumumabClinical trialsIndustry payments5Publications13

Works with

trial sponsors and companies reporting payments
Mayo ClinicClinical trials9Industry paymentsJanssen Biotech, Inc.Clinical trialsIndustry payments5Celgene CorporationClinical trialsIndustry payments4

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
2,490publications

Distinct works indexed by OpenAlex, matched via ORCID; 194 in PubMed.

100,475citations

Total citations across indexed works.

146h-index

Hirsch index (OpenAlex). i10-index 877.

Clinical & industry

trials, payments and federal funding
13clinical trials

Investigator role on registered studies.

View trials
9companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
5NIH grants · 2001–2022

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    50.8%
    Other drugs affecting bone structure and mineralization50.8%
    Romosozumab-aqqg100%
    Part B, office-administered11 patients
  • Anti-infectives

    42.6%
    SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor42.3%
    Remdesivir100%
    Part B, office-administered13 patients
    Short-acting sulfonamides0.3%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
  • Cancer & immunology

    2%
    Thalidomide Analog1.6%
    Revlimid66%Lenalidomide34%
    Part D<11 patients
    BCL-2 Inhibitor0.4%
    Venclexta100%
    Part D<11 patients
6 more therapeutic areas behind the reveal.Reveal →
Where care is delivered (Part B)2.1% facility · 97.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

5 NIH research awards on record, funded 20012022 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/angela-dispenzieri-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • X / Twitter

    x.com/ADispenzieri

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    bloodcancerstoday.com/podcast/angela-dispenzieri-md-on-managing-newly-diagnosed-al-amyloidosis

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →bloodcancerstoday.com
  • Other

    vjhemonc.com/speaker/angela-dispenzieri

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com
  • ResearchGate

    researchgate.net/scientific-contributions/Angela-Dispenzieri-2161930600

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net
2 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • Resident/Fellow

    Hematology and Oncology, Mayo Graduate School of Medicine, Mayo Clinic College of Medicine

    1998
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
  • Board Certification: Hematology

    American Board of Internal Medicine

    1997
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
  • Resident

    Internal Medicine, Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine

    1994
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
  • MD

    Albert Einstein College of Medicine

    1991
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
  • Undergraduate study

    Massachusetts Institute of Technology (per Mayo biographical summary; degree/year not specified on primary page)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org

Editorial & leadership roles

journal and society appointments
  • President

    International Kidney Monoclonal Gammopathy Research Group

    2024
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
  • Member

    NCI Myeloma Steering Committee

    2023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
  • Member

    Performance Expectations for Clinical Trialists Taskforce

    2022
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org
5 more roles behind the reveal.Reveal →

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com
  • Cross-Field
    201920222023
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com

Awards & honors

honors on the public record
4 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
1 more affiliation behind the reveal.Reveal →

Media & interviews

press, podcasts and appearances
2 more media items behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.